ReviewFrontiers in endocrinology2026
The CKM-GDM multi-organ precision model: reframing gestational diabetes as an early cardiovascular-kidney-metabolic event in Southeast Asia.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gestational diabetes mellitus (GDM) is amongst the commonest complications of pregnancy and an early marker of lifetime cardiovascular-kidney-metabolic (CKM) risk. Its burden is heavy in Southeast Asia, where prevalence ranges from about 8% to nearly 30% and a lean phenotype - with marked over-representation of the insulin-secretion-limited subtype - diverges from Western cohorts, yet its definition, timing, and treatment remain contested. Aim: This clinically oriented narrative review synthesises the diagnostic landscape, the shift to early diagnosis, the vascular mechanism, and precision care, centred on Southeast Asia. Key themes: Competing criteria (IADPSG one-step, WHO 2013, NICE, ADA two-step and the pragmatic Indian DIPSI test) identify different populations. The TOBOGM trial shows that early (pre-20-week) treatment improves outcomes, and first-trimester biomarkers-low adiponectin and sex-hormone-binding globulin, glycosylated fibronectin, atherogenic lipids, and multimarker or machine-learning panels including a non-fasting Asian-women panel-show potential to make early prediction feasible. Vascular and endothelial dysfunction (oxidative stress, eNOS uncoupling, sFlt-1/PlGF imbalance, and arterial stiffness) is proposed as the unifying early signal and a mechanistic bridge to later type 2 diabetes, cardiovascular disease, and chronic kidney disease. GDM is increasingly recognised as heterogeneous (insulin-resistant, insulin-deficient, and mixed subtypes), inviting subtype- and phenotype-guided precision diagnosis and treatment. Conclusion: We propose that GDM may be productively reframed as an early, vascular, and potentially precisely treatable CKM event-screened early, matched to phenotype and linked to lifelong follow-up, and fitted to the epidemiology, genetics, and health systems of Southeast Asia. This reframing is a testable hypothesis that requires prospective validation before routine adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.